Fixed and separate combination of solifenacin and tamsulosin in urinary disorders associated with benign prostatic hyperplasia: a choice based on price and value comparison

Objective. To determine the consequences of the use of a fi xed combination of solifenacin and tamsulosin in patients whom recommended the prescription of these drugs. Methods. Analysis of prices of drugs solifenacin + tamsulosin controlled release (Vasomni), solifenacin (Vesicare), tamsulosin controlled release (Omnic Okas) and tamsulosin modifi ed-release (several registered trade names of the drug) conducted on the basis of information from several sources: 1 — the register of maximum ex-works prices of manufacturers of vital and essential medicines, 2 — data on average prices in pharmacies of Moscow (as of 15.02.2018), 3 — weighted average prices of public procurement for 2018 according to the monitoring of the pharmaceutical market. To determine the points of relative value of drugs, a survey of experts was conducted: 1 — to determine the values of the criteria for the drugs under consideration — urologists; 2 — to determine the weight of the criteria — persons involved in the decision-making on the selection and purchase of drugs. Results. We found that the cost of the equivalent course dose of Vesomni was on 40-42 % lower than the combination of drugs Vesicar and Omnik Okas. Compared with the non-fi xed combination of solifenacin with tamsulosin in a drug form with modifi ed release, no signifi cant diff erences in price levels were found. At the same time, the relative value of a fi xed combination is 5-6 percentage points higher compared to non-fi xed combinations, mainly due to ease of use. Conclusion. Use of a fi xed combination of solifenacin + tamsulosin can lead to budget savings with an increase in the level of relative value.

1. Zyryanov SK, Dyakov IN. Farmakoehkonomicheskaya celesoobraznost primeneniya kombinirovannogo preparata Vezomni po sravneniyu s kombinaciej tamsulozina i solifenacina v vide monopreparatov. Kachestvennaya klinicheskaya praktika 2018;1:35—40. (In Russ). DOI: 10.24411/2588-0519-2018-10036.

2. Tolkushin AG, Davydovskaya MV, Yagudina RI. The concept of determining the equilibrium price of innovative drugs based on their real value — value-based pricing. Remedium. 2017;12:6—14. (In Russ). DOI: 10.21518/1561-5936-2017-12-6-14.

3. Avxentyev NA, Frolov MYu. Pharmacoeconomic analysis of Vesomni (solifenacin and controlled release tamsulosin) treatment of storage symptoms associated with benign prostatic hyperplasia. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2016;2:3—10 (In Russ). DOI: 10.17749/2070-4909.2016.9.2.003-010.

4. Alyaev YuG, Glybochko PV, Pushkar’ DYu. Urologiya. Rossijskie klinicheskie rekomendacii. Moscow: Medforum; 2018. (In Russ).

5. Romancik M, Pandian S, Drake MJ. Tamsulosin/solifenacin fixed-dose combination tablet for the treatment of male lower urinary tract symptoms. Drugs of Today. 50(12):803—811. DOI: 10.1358/dot.2014.50.12.2247444.

6. Zyryanov SK, Dyakov IN. Farmakoehkonomicheskaya celesoobraznost primeneniya kombinirovannogo preparata Vezomni po sravneniyu s kombinaciej tamsulozina i solifenacina v vide monopreparatov. Kachestvennaya klinicheskaya praktika 2018;1:35—40. (In Russ). DOI: 10.24411/2588-0519-2018-10036.

7. Avxentyev NA, Frolov MYu. Pharmacoeconomic analysis of Vesomni (solifenacin and controlled release tamsulosin) treatment of storage symptoms associated with benign prostatic hyperplasia. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2016;2:3—10 (In Russ). DOI: 10.17749/2070-4909.2016.9.2.003-010.

8. Romancik M, Pandian S, Drake MJ. Tamsulosin/solifenacin fixed-dose combination tablet for the treatment of male lower urinary tract symptoms. Drugs of Today. 50(12):803—811. DOI: 10.1358/dot.2014.50.12.2247444.